Regional hyperthermia (RHT) combined with gemcitabine (G) plus cisplatin (P) in patients (pts) with advanced pancreatic adenocarcinoma (APC)

被引：0
|
作者：
Tschoep, K. E. [1 ]
Milani, V. [1 ]
Lindner, L. H. [1 ]
Boeck, S. [1 ]
Berger, F. [2 ]
Dieterle, N. [1 ]
Abdel-Rahman, S. [1 ]
Salat, C. [3 ]
Issels, R. D. [1 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-8000 Munich, Germany
[2] Univ Munich, Klinikum Grosshadern, Klin Nukl Med, D-8000 Munich, Germany
[3] Hamatoonkol Schwerpunktpraxis & Tagesklin, Munich, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：80 / 80
页数：1
相关论文
共 50 条
  • [31] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [32] Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
    Kindler, Hedy L.
    Ioka, Tatsuya
    Richel, Dirk J.
    Bennouna, Jaafar
    Letourneau, Richard
    Okusaka, Takuji
    Funakoshi, Akihiro
    Furuse, Junji
    Park, Young Suk
    Ohkawa, Shinichi
    Springett, Gregory M.
    Wasan, Harpreet S.
    Trask, Peter C.
    Bycott, Paul
    Ricart, Alejandro D.
    Kim, Sinil
    Van Cutsem, Eric
    LANCET ONCOLOGY, 2011, 12 (03) : 256 - 262
  • [33] Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study
    Inal, A.
    Kos, F. T.
    Algin, E.
    Yildiz, R.
    Berk, V.
    Unek, I. Tugba
    Colak, D.
    Kucukoner, M.
    Elkiran, E. Tamer
    Helvaci, K.
    Geredeli, C.
    Dane, F.
    Balakan, O.
    Kaplan, M. Ali
    Durnali, A. Gok
    Harputoglu, H.
    Goksel, G.
    Ozdemir, N.
    Buyukberber, S.
    Gumus, M.
    Ozkan, M.
    Benekli, M.
    Isikdogan, A.
    JOURNAL OF BUON, 2012, 17 (01): : 102 - 105
  • [34] Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in pts with advanced solid tumors
    Subbiah, V.
    Combest, A.
    Griley-Olsen, J.
    Sharma, N.
    Andrews, E.
    Bobe, I.
    Balkissoon, J.
    Camp, A.
    Masada, A.
    Reitsma, D.
    Bazhenova, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] The role of response as predictor of improved outcome in advanced pancreatic cancer (APC) patients (pts) treated with first-line Gemcitabine plus Nab-paclitaxel (GemNab).
    Bensi, Maria
    Di Stefano, Brunella
    Bagala, Cinzia
    Spring, Alexia
    Chiaravalli, Marta
    Ribelli, Marta
    Camarda, Floriana
    Maratta, Maria Grazia
    Tortora, Giampaolo
    Salvatore, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Gemcitabine (G) plus nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.
    Chan, Edmond Mankee
    Hong, Theodore S.
    Clark, Jeffrey William
    Blaszkowsky, Lawrence Scott
    Allen, Jill N.
    Zhu, Andrew
    Goyal, Lipika
    Murphy, Janet E.
    Kwak, Eunice L.
    Wo, Jennifer Y.
    Ryan, David P.
    Faris, Jason Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
    Borazanci, Erkut Hasan
    Jameson, Gayle S.
    Snyder, Courtney Edwards
    Thosani, Amar
    Sckolnik, Steven
    Korn, Ronald Lee
    Rahmanuddin, Syed
    Mocan, Dan
    Pearse, Shelby
    Gordon, Michael S.
    Von Hoff, Daniel D.
    Modasi, Aryan
    Amini, Albert
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 667 - 667
  • [38] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [39] Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
    H Ulrich-Pur
    M Raderer
    G Verena Kornek
    B Schüll
    K Schmid
    K Haider
    W Kwasny
    D Depisch
    B Schneeweiss
    F Lang
    W Scheithauer
    British Journal of Cancer, 2003, 88 : 1180 - 1184
  • [40] A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC)
    Saif, M. W.
    Li, J.
    Lamb, L.
    Rosenberg, A.
    Elligers, K.
    Ruta, S.
    Mezes, M.
    Grant, N.
    Liu, S. H.
    Chu, E.
    Cheng, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345